Abstract
Purpose
The purpose was to evaluate the effects of long-term anti-VEGF treatment on the retinal nerve fiber layer (RNFL) and retinal ganglion cell layer (RGCL) thickness for patients with neovascular AMD and glaucoma.
Methods
Medical records of respective patients who had received more than 15 anti-VEGF injections were reviewed. Initial and latest SD-OCT macular scans were segmented and changes of the RNFL and RGCL thickness at the four outer ETDRS quadrants were evaluated. Secondary outcome measures included changes of visual field parameters seen in automated perimetry.
Results
Sixteen patients were included (mean age 78 ± 6 years). The mean total number of anti-VEGF injections was 39 ± 16. The mean treatment duration was 6.1 ± 2.1 years. The mean IOP decreased from 18 ± 5 mmHg at baseline to 15 ± 5 mmHg at the last visit (p = 0.026). The mean RNFL thickness volume of the outer ETDRS quadrants (0.98 ± 0.18 mm3 to 0.97 ± 0.18 mm3 p = 0.61) and its average thickness (37.9 ± 7.3 μm to 37.2 ± 7.4 μm, p = 0.6) did not significantly change. However, the average RGCL thickness decreased significantly from 0.86 ± 0.12 mm3 to 0.79 ± 0.11 mm3 (p = 0.01), and from 27.7 ± 4.2 to 25.9 ± 3.7 μm (p = 0.01). Number of injections correlated with the RGCL change (r2 = 0.36, p = 0.01). The mean sensitivity, mean defect and absolute scotomata did not significantly change with p-values of 0.28, 0.21 and 0.07, respectively.
Conclusion
Patients under long term treatment with anti-VEGF and concurrent glaucoma show significant decrease in macular RGLC volume. However, this decrease is comparable to reported RGCL decrease in patients under anti-VEGF treatment without underlying glaucoma and suggests that glaucoma patients may not be at a higher risk for losing macular RNFL and RGCL, at least if adequate control of intraocular pressure is maintained.
Similar content being viewed by others
References
Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589–597. doi:10.1001/jamaophthalmol.2015.186
Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A, EXCITE Study Group (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831–839. doi:10.1016/j.ophtha.2010.09.004
Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663–671. doi:10.1016/j.ophtha.2010.12.019
Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114. doi:10.1136/bjo.2010.180729
Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930–934 e931. doi:10.1016/j.ajo.2008.07.007
Dedania VS, Bakri SJ (2015) Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina 35:841–858. doi:10.1097/IAE.0000000000000520
Quigley HA (1999) Neuronal death in glaucoma. Prog Retin Eye Res 18:39–57
Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, Witt KA (1991) Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol 109:77–83
Quigley HA, Dunkelberger GR, Green WR (1989) Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 107:453–464. doi:10.1016/0002-9394(89)90488-1
Airaksinen PJ, Drance SM, Douglas GR, Mawson DK, Nieminen H (1984) Diffuse and localized nerve fiber loss in glaucoma. Am J Ophthalmol 98:566–571
Zeimer R, Asrani S, Zou S, Quigley H, Jampel H (1998) Quantitative detection of glaucomatous damage at the posterior pole by retinal thickness mapping: a pilot study. Ophthalmology 10:224–231
Chiu SJ, Li XT, Nicholas P, Toth CA, Izatt JA, Farsiu S (2010) Automatic segmentation of seven retinal layers in SDOCT images congruent with expert manual segmentation. Opt Express 18:19413–19428. doi:10.1364/OE.18.019413
Ishikawa H, Stein DM, Wollstein G, Beaton S, Fujimoto JG, Schuman JS (2005) Macular segmentation with optical coherence tomography. Invest Ophthalmol Vis Sci 46:2012–2017. doi:10.1167/iovs.04-0335
Demirel S, Batioglu F, Ozmert E, Erenler F (2015) The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res 40:87–92. doi:10.3109/02713683.2014.917190
Horsley MB, Mandava N, Maycotte MA, Kahook MY (2010) Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 150:558–561 e551. doi:10.1016/j.ajo.2010.04.029
Rimayanti U, Kiuchi Y, Yamane K, Latief MA, Mochizuki H, Hirata J, Akita T, Tanaka J (2014) Inner retinal layer comparisons of eyes with exudative age-related macular degeneration and eyes with age-related macular degeneration and glaucoma. Graefes Arch Clin Exp Ophthalmol 252:563–570. doi:10.1007/s00417-013-2496-z
Menke MN, Zinkernagel MS, Ebneter A, Wolf S (2014) Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. Br J Ophthalmol 98:1197–1200. doi:10.1136/bjophthalmol-2013-304775
Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489–1506. doi:10.1097/IAE.0000000000000627
Katayama BY, Bonini-Filho MA, Messias AM, Paula JS, Martin LF, Costa R, Jorge R (2014) Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma 23:461–463. doi:10.1097/IJG.0b013e3182948476
Griffith JF, Goldberg JL (2015) Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center. Clin Ophthalmol 9:1275–1284. doi:10.2147/OPTH.S85851
Shin HJ, Shin KC, Chung H, Kim HC (2014) Change of retinal nerve fiber layer thickness in variousretinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci 55:2403–2411. doi:10.1167/iovs.13-13769
Zucchiatti I, Parodi MB, Pierro L, Cicinelli MV, Gagliardi M, Castellino N, Bandello F (2015) Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration. Am J Ophthalmol 160:602–607 e601. doi:10.1016/j.ajo.2015.05.030
Lee EK, Yu HG (2015) Ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer thicknesses in age-related macular degeneration. Invest Ophthalmol Vis Sci 56:3976–3983. doi:10.1167/iovs.15-17013
Beck M, Munk MR, Ebneter A, Wolf S, Zinkernagel MS (2016) Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 167:10–17. doi:10.1016/j.ajo.2016.04.003
Harwerth RS, Wheat JL, Rangaswamy NV (2008) Age-related losses of retinal ganglion cells and axons. Invest Ophthalmol Vis Sci 49:4437–4443. doi:10.1167/iovs.08-1753
Curcio CA, Medeiros NE, Millican CL (1996) Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci 37:1236–1249
Garas A, Papp A, Hollo G (2013) Influence of age-related macular degeneration on macular thickness measurement made with fourier-domain optical coherence tomography. J Glaucoma 22:195–200. doi:10.1097/IJG.0b013e31824083e6
Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214–6218. doi:10.1167/iovs.12-9875
Yuda K, Inoue Y, Tomidokoro A, Tamaki Y, Yanagi Y (2010) Nerve fiber layer thickness in exudative age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol 248:353–359. doi:10.1007/s00417-009-1222-3
Dunaief JL, Dentchev T, Ying GS, Milam AH (2002) The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 120:1435–1442
Shin HY, Park HY, Jung KI, Park CK (2013) Comparative study of macular ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer measurement: structure-function analysis. Invest Ophthalmol Vis Sci 54:7344–7353. doi:10.1167/iovs.13-12667
Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D (2009) Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology 116:2305–2314 e2301–2302. doi:10.1016/j.ophtha.2009.05.025
Kim NR, Lee ES, Seong GJ, Kim JH, An HG, Kim CY (2010) Structure–function relationship and diagnostic value of macular ganglion cell complex measurement using Fourier-domain OCT in glaucoma. Invest Ophthalmol Vis Sci 51:4646–4651. doi:10.1167/10.1167/iovs.09-5053
Girkin CA, McGwin G Jr, Sinai MJ, Sekhar GC, Fingeret M, Wollstein G, Varma R, Greenfield D, Liebmann J, Araie M, Tomita G, Maeda N, Garway-Heath DF (2011) Variation in optic nerve and macular structure with age and race with spectral-domain optical coherence tomography. Ophthalmology 118:2403–2408. doi:10.1016/j.ophtha.2011.06.013
Budenz DL, Anderson DR, Varma R, Schuman J, Cantor L, Savell J, Greenfield DS, Patella VM, Quigley HA, Tielsch J (2007) Determinants of normal retinal nerve fiber layer thickness measured by Stratus OCT. Ophthalmology 114:1046–1052. doi:10.1016/j.ophtha.2006.08.046
Patel PJ, Chen FK, da Cruz L, Tufail A (2009) Segmentation error in Stratus optical coherence tomography for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 50:399–404. doi:10.1167/iovs.08-1697
Lee HJ, Kim MS, Jo YJ, Kim JY (2015) Ganglion cell-inner plexiform layer thickness in retinal diseases: repeatability study of spectral-domain optical coherence tomography. Am J Ophthalmol 160:283–289 e281. doi:10.1016/j.ajo.2015.05.015
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for this research. Martin S Zinkernagel is a stock holder and a consultant for Novartis and a consultant for Bayer. Marion R Munk is a consultant for Novartis and Bayer and received travel grants from Bayer. The remaining authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Financial support
None.
Conflict of interest
The authors have no conflict of interest to report.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplemental Table 1
(DOCX 16 kb)
Supplemental Fig. 1
Scatter blot of average retinal nerve fiber layer (RNFL) thickness of the ETDRS outer rings in patients with glaucoma and neovascular age-related macular degeneration under long-term anti-VEGF treatment at baseline (BL) and last follow-up visit (FU). No significant changes were noted over time. (GIF 13 kb)
Supplemental Fig. 2
Scatter blot of average the retinal ganglion cell layer (RGCL) thickness of the ETDRS outer rings in patients with glaucoma and neovascular age-related macular degeneration under long-term anti-VEGF treatment at baseline (BL) and last follow-up visit (FU).at baseline (BL) and last follow-up visit (FU). Significant decrease of RGCL thickness was noted over time. (GIF 14 kb)
Rights and permissions
About this article
Cite this article
Saleh, R., Karpe, A., Zinkernagel, M.S. et al. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration. Graefes Arch Clin Exp Ophthalmol 255, 817–824 (2017). https://doi.org/10.1007/s00417-017-3590-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-017-3590-4